Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
FDA Milestone | Nuvation Bio's IBTROZI approval for ROS1-positive NSCLC marks its transition to a commercial-stage company, potentially reshaping its market position and financial outlook. |
Competitive Edge | Explore IBTROZI's advantages in efficacy, brain metastasis treatment, and dosing schedule, positioning it as a potential best-in-class therapy in a competitive market. |
Market Dynamics | Delve into anticipated NCCN guideline changes and increased NGS testing, which could drive higher utilization of ROS1 TKIs and expand IBTROZI's market potential. |
Financial Prospects | Analysts project price targets ranging from $6 to $10, reflecting optimism about IBTROZI's commercial potential despite current stock volatility and market uncertainties. |
Metrics to compare | NUVB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNUVBPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.9x | 16.3x | −0.5x | |
PEG Ratio | −0.05 | 0.05 | 0.00 | |
Price/Book | 2.1x | 5.1x | 2.6x | |
Price / LTM Sales | 54.5x | 1.6x | 3.3x | |
Upside (Analyst Target) | 180.8% | 315.3% | 43.5% | |
Fair Value Upside | Unlock | 22.2% | 6.8% | Unlock |